Evergreen Theragnostics
Evergreen Theragnostics manufactures radioactive cancer medicines for other companies and develops its own imaging agent for neuroendocrine tumours and a treatment for small cell lung cancer. Lantheus agreed to buy it in 2025.
Overview
Evergreen Theragnostics is a Springfield, New Jersey radiopharmaceutical company combining contract development and manufacturing (CDMO) services with proprietary products. Its facility, completed in October 2021, has produced clinical material for partners including Clovis Oncology (225Ac FAP-2286), Clarity (copper theranostics), MTTI and Precirix (CAM-H2). Proprietary programmes include OCTEVY, a registrational-stage PET diagnostic for neuroendocrine tumours, and EVG321, a CCK2 receptor-targeted radioligand licensed from the Medical University of Innsbruck in May 2024 for small cell lung cancer, with the CCK2-VIEW phase 2 trial opened in the EU in October 2024. In January 2025 Lantheus agreed to acquire Evergreen for USD 250 million upfront and up to USD 752.5 million in milestones, to become a fully integrated radiopharmaceutical company.
Funding
All companiesInvestors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · USD 250 million upfront plus up to USD 752.5 million in milestones; all-cash, announced 28 January 2025 | 2025 | $250M | evergreentgn.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Notes
top- Venture financing before the acquisition not fetched and omitted. Completion of the Lantheus deal not confirmed from a fetched page, although the company site now links to Lantheus careers and pipeline.
Similar pages
not linked directly; found by shared links- CompanyAriceum Therapeutics
Shares Small-cell lung cancer, Actinium-225, Radioligand therapy (beta emitters).
- CompanyAlpha-9 Oncology
Shares PET (positron emission tomography), Actinium-225, Radioligand therapy (beta emitters).
- CompanyMariana Oncology
Shares Small-cell lung cancer, Radioligand therapy (beta emitters).
- TrialStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
- CompanyMolecular Targeting Technologies
Shares Small-cell lung cancer, Neuroendocrine tumours, Actinium-225.
- CompanyRatio Therapeutics
- CompanyAbdera Therapeutics
Shares Small-cell lung cancer, Radioligand therapy (beta emitters).
- TermNeuroendocrine tumour grade (Ki-67) and WHO classification